Rundu Co., Ltd. announced that it has recently received two “Drug Registration Certificates” for mesartan potassium tablets issued by the State Drug Administration. The drug is suitable for the treatment of essential hypertension in adults. The company's API product measartan potassium obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the State Drug Administration in August 2024. This time, measartan potassium tablets were approved for drug registration, further improving the company's product layout in the field of cardiovascular and cerebrovascular treatment, enriching the company's product matrix, and promoting the formation of a vertically integrated industrial chain from APIs to formulations, which helps enhance overall market competitiveness and is in line with the company's development strategy.

Rundu Co., Ltd. announced that it has recently received two “Drug Registration Certificates” for mesartan potassium tablets issued by the State Drug Administration. The drug is suitable for the treatment of essential hypertension in adults. The company's API product measartan potassium obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the State Drug Administration in August 2024. This time, measartan potassium tablets were approved for drug registration, further improving the company's product layout in the field of cardiovascular and cerebrovascular treatment, enriching the company's product matrix, and promoting the formation of a vertically integrated industrial chain from APIs to formulations, which helps enhance overall market competitiveness and is in line with the company's development strategy.